- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05982691
Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors
National Cancer Center Korea
<Purpose of the Research>
- Primary Establishing an Asian consortium to establish a database of pediatric CNS tumors in the prospective manner The target disease of this research focuses on pediatric tumors, and initially the registration of patients with CNS GCT will begin first.
- Secondary Developing clinical protocols for pediatric CNS tumors based in Asia
<Duration of Research Participation> Registration period for research subjects: 2022-08-01 - 2027-12-31 Duration of medical records to be utilized: to 2030-12-31 Total projected duration of research: IRB approved to 2032-12-31 Interim assessment of data quality and integrity: 6 Mo after Data collection Evaluation for the Adaptation of Protocols: 1 and 2 years after the initiation of the study Analysis of Quality of Life and other questionnaires: 3 and 5 years Interim Analysis of all data: 5 years (2027) Final analysis of treatment outcome: 2032
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
<Selection standards>
A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.
Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).
The age at the time of diagnosis is 0< ≤40 years
A patent who has been diagnosed with the relevant tumor via an operation or a biopsy ⑤In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value;
- Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)
<Exclusion criteria> ①The patient or the guardian of the patient did not consent to participate.
<Attrition criteria>
The patient refuses the treatment plan when the treatment is not completed.
The consent to participate has been rescinded in the process of data collection after the completion of the treatment.
③The research subject expresses the intention to rescind the consent to participate after the subject reaches the age of majority.
<Recruitment through an international multi-agency network> Managers at Korean institutions who agreed to participate in the research are charged with the registration of patient information. Internationally, researchers in each institution in Singapore, Taiwan, Thailand, and Korea which agreed to participate in the research enter the information by logging into a registration system.
Each institution obtained approval from its respective institutional review board.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Joo-Young Kim, M.D., Ph.D.
- Phone Number: +82 31 920 1724
- Email: jooyoungcasa@ncc.re.kr
Study Contact Backup
- Name: songei Yang, MPH
- Phone Number: +82-31-920-0155
- Email: yse1213@ncc.re.kr
Study Locations
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
- Recruiting
- National Cancer Center, Korea
-
Contact:
- Joo-Young Kim, M.D., Ph.D.
- Phone Number: +82 31 920 1724
- Email: jooyoungcasa@ncc.re.kr
-
Principal Investigator:
- Joo-Young Kim, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.
Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).
The age at the time of diagnosis is 0< ≤40 years
- A patent who has been diagnosed with the relevant tumor via an operation or a biopsy ⑤ In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value; -Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)
Exclusion Criteria:
① The patient or the guardian of the patient did not consent to participate.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic and diagnostic elements
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Laboratory and pathologic assessments
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Radiological assessments
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Radiologic response criteria
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Treatment elements
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Treatment response, acute and late complications, and survival
Time Frame: Untill the year 2027
|
|
Untill the year 2027
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neurocognitive assessment
Time Frame: Untill the year 2027
|
• Neurocognitive functions of patients are highly recommended to be assessed before the initiation of treatment (either chemotherapy or radiotherapy) and at 1 years post-treatment, and every 1-2 years thereafter after the completion of all treatment.
|
Untill the year 2027
|
Quality of life assessment
Time Frame: Untill the year 2027
|
• Under the standard treatment, conduct a survey before initial treatment either chemotherapy or radiotherapy, 1 years post-treatment, and every 1-2 years thereafter after the completion of all treatment (Those who underwent chemotherapy before radiotherapy need to undergo first survey before chemotherapy and additionally a second survey before radiotherapy)
|
Untill the year 2027
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joo-young Kim, M.D., Ph.D., National Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC22-0194
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CNS Tumor
-
GenmabBioNTech SERecruiting
-
St. Jude Children's Research HospitalWithdrawnRhabdoid Tumor | CNS Tumor | Atypical Teratoid/Rhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor of CNSUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterRecruitingSolid Tumor | CNS TumorFrance, Germany, Australia, Austria, Sweden, Netherlands, Switzerland
-
St. Jude Children's Research HospitalRecruitingSolid Tumor | CNS Tumor | ALL, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterRockefeller UniversityCompletedPrimary or Metastatic Central Nervous System (CNS) TumorUnited States
-
Blueprint Medicines CorporationRecruitingCNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid NeoplasmUnited States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
-
Chengcheng GuoRecruitingSurgery | Intracranial Germ Cell Tumor | Intracranial Germ Cell CNS Tumor, ChildhoodChina
-
Arbor Pharmaceuticals, Inc.Active, not recruiting
-
Huashan HospitalUnited Imaging HealthcareRecruiting
-
Rigshospitalet, DenmarkRecruitingCNS Tumor, ChildhoodDenmark
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
NYU Langone HealthCompletedBreast CancerUnited States
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States